leisure time -WSS

leisure time

author：focus 2025-10-02 21:06:16 - browse：6386

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Inequities make cancer less preventable for women: report

knowledge

WSS

Senator probes 340B programs at Cleveland Clinic, Bon Secours

How one patient went off dialysis — and others can too

Health tech startups drop sharply from 2021 highs

Address the ethical violations that led to 'Three Identical Strangers'

Address the ethical violations that led to 'Three Identical Strangers'

UnitedHealth, Optum discontinue NaviHealth name

hotspot

leisure time

hotspot

Jerome Adams on the need for new antivirals for Covid

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Apple is now the first public company to be valued at $3 trillion

STAT Summit: How researchers deal with rejection

Walensky prepares to leave CDC — and Congress — behind

How one patient went off dialysis — and others can too

Dobbs anniversary: the lost opportunity of abortion as health care

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

leisure time

FDA seeks to regulate lab

STAT Summit: Meghan O’Rourke on making chronic illness visible

Inequities make cancer less preventable for women: report

Covid vaccines: Private market messier than government rollout

How one patient went off dialysis — and others can too

Biogen shutters digital health group, ends Apple study, in cost cutting move

knowledge

focus

leisure time

hotspot